Indrani W Gunawardana

6579882, Jun 17, 2003

Mar 6, 2001

09/799729

Andrew O. Stewart - Libertyville IL
Steven A. Boyd - Mundelein IL
David L. Arendsen - Libertyville IL
Pramila Bhatia - Libertyville IL
Kevin R. Condroski - Evanston IL
Jennifer C. Freeman - Grayslake IL
Indrani W. Gunawardana - Libertyville IL
Kraig Lartey - Waukegan IL
Catherine M. McCarty - Brookline MA
Nicholas A. Mort - Highland Park IL
Meena V. Patel - Chicago IL
Michael A. Staeger - Greenfield WI
David M. Stout - Libertyville IL

Abbott Laboratories - Abbott Park IL

A61K 31519

514258, 544278

Compounds having Formula I are useful for treating inflammation. Also disclosed are pharmaceutical compositions comprising compounds of Formula I, and methods of inhibiting/treating inflammatory diseases in a mammal.

6693123, Feb 17, 2004

Oct 30, 2001

09/984411

Said M. Sebti - Tampa FL
Andrew D. Hamilton - Guilford CT
David J. Augeri - Kenosha WI
Kenneth J. Barr - Chicago IL
Greg B. Donner - Mundelein IL
Stephen A. Fakhoury - Mundelein IL
Stephen J. OConnor - Wilmette IL
Saul H. Rosenberg - Grayslake IL
Wang Shen - Gurnee IL
Bruce G. Szczepankiewicz - Lindenhurst IL
Indrani W. Gunawardana - Libertyville IL

University of Pittsburgh - Pittsburgh PA

A61K 3144

514357, 514352, 51425505, 514256, 544238, 544333, 544405, 546264, 546266, 548252, 549321

Compounds having the formula or a pharmaceutically acceptable salt thereof wherein R is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L â, and (i) heterocyclic-L is selected from (e) âC(O)NHâCH(R )-tetrazolyl, (f) âC(O)NH-heterocyclic, and (g) âC(O)NHâCH(R )âC(O)NR R ; R is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L is absent or is selected from (a) âL âN(R )âL â, (b) âL âOâL â, (c) âL âS(O) âL â (d) âL âL âC(W)âN(R )âL â, (e) âL âL âS(O) âN(R )âL â, (f) âL âN(R )âC(W)âL âL â, (g) âL âN(R )âS(O) âL âL â, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.

6867203, Mar 15, 2005

Dec 1, 2003

10/725212

Indrani W. Gunawardana - Libertyville IL, US

Abbott Laboratories - Abbott Park IL

A61K031/33
A61K031/405
C07D295/00
C07D239/00
C07D235/24

514183, 514295, 514395, 514415, 514712, 544106, 544253, 546183, 5483064, 549362, 549469, 568 38, 568 58

The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases and cerebral vasospasm, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.

6878700, Apr 12, 2005

Mar 31, 2000

09/541795

James Link - Evanston IL, US
Gang Liu - Gurnee IL, US
ZhongHua Pei - Libertyville IL, US
Tom von Geldern - Richmond IL, US
Martin Winn - Deerfield IL, US
Zhili Xin - Lake Bluff IL, US
Steven A. Boyd - Mundelein IL, US
Jennifer C. Freeman - Grayslake IL, US
Indrani W. Gunawardana - Libertyville IL, US
Michael A. Staeger - Greenfield WI, US
Hwan-Soo Jae - Glencoe IL, US
John K. Lynch - Kenosha WI, US
Sheldon Wang - Carmel IN, US

Abbott Laboratories - Abbott Park IL

A61K031/33
A61K031/415
C07D265/30
C07D221/02
C07D319/00

514183, 514295, 514395, 514415, 514712, 544106, 544253, 544283, 544282, 546183, 5483064, 549362, 549469

The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immunune diseases, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.

7879885, Feb 1, 2011

Mar 23, 2005

10/593911

Steven A. Boyd - Longmont CO, US
Kevin R. Condroski - Broomfield CO, US
Allen Thomas - Louisville CO, US
Stephen S. Gonzales - Media PA, US
Indrani W. Gunawardana - Longmont CO, US
Yvan Le Huerou - Boulder CO, US
Todd T. Romoff - Firestone CO, US
Francis X. Sullivan - Boulder CO, US

Array Biopharma, Inc. - Boulder CO

A61K 31/44

514357, 546 6, 546329

The present invention provides thioalkeneamides of formula (I) which are useful as transketolase inhibitors: wherein R, R, R, R, R, R, R-R, n and ring A are as defined herein. The present invention also provides pharmaceutical compositions comprising the compounds of formula (I). The invention provides methods for inhibiting transketolase activity, reducing cellular ribose-5-phosphate levels, inhibiting nucleic acid synthesis, inhibiting cell proliferation and tumor cell growth in vitro and in vivo, stimulating apoptosis in tumor cells and treating cancer by administering a compound of formula (I) or a pharmaceutical composition thereof.

8178131, May 15, 2012

May 13, 2009

12/992468

Yvan Le Huerou - Boulder CO, US
James F. Blake - Boulder CO, US
Indrani W. Gunawardana - Boulder CO, US
Peter J. Mohr - Boulder CO, US
Eli M. Wallace - Boulder CO, US
Bin Wang - Boulder CO, US
Mark Joseph Chicarelli - Boulder CO, US
Michael Lyon - Boulder CO, US

Array BioPharma Inc. - Boulder CO

A61K 33/24
A61K 31/437
A61K 31/7068
A61K 31/4745
A61K 31/513
A61K 31/497
A61K 31/506
A61K 31/501
A61K 31/498
A61K 31/5377
A61K 31/55
A61P 35/00
C07D 471/04

424649, 51421018, 51421021, 51421707, 5142328, 514249, 51425201, 51425505, 514256, 514274, 514283, 514300, 514 49, 540597, 544127, 544238, 544333, 544355, 544405, 546113

Compounds of Formula (I) are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

8212045, Jul 3, 2012

Sep 15, 2008

12/678995

Thomas Daniel Aicher - Superior CO, US
Steven Armen Boyd - Longmont CO, US
Mark Joseph Chicarelli - Longmont CO, US
Kevin Ronald Condroski - Lafayette CO, US
Jay Bradford Fell - Longmont CO, US
John P. Fischer - Longmont CO, US
Indrani W. Gunawardana - Longmont CO, US
Ronald Jay Hinklin - Longmont CO, US
Ajay Singh - Longmont CO, US
Timothy M. Turner - Longmont CO, US
Eli M. Wallace - Lyons CO, US

Array BioPharma, Inc. - Boulder CO

A61K 31/44
C07D 417/00

5462687, 5462697, 514342

Provided are compounds of Formula (I): wherein R, R, R, L and Dare as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

8372842, Feb 12, 2013

Jan 8, 2009

12/812448

James F. Blake - Boulder CO, US
Indrani W. Gunawardana - Boulder CO, US
Yvan Le Huerou - Boulder CO, US
Peter J. Mohr - Boulder CO, US
Eli M. Wallace - Boulder CO, US
Bin Wang - Boulder CO, US

Array BioPharma Inc. - Boulder CO

A61K 31/496
C07D 471/04

51425304, 544362

Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.